Viral diseases are prominent among the widely spread infections threatening human well-being. Real-life clinical successes of the few available therapeutics are challenged by pathogenic resistance and suboptimal delivery to target sites. Nanotechnology has aided the design of functionalised and non-functionalised Au and Ag nanobiomaterials through physical, chemical and biological (green synthesis) methods with improved antiviral efficacy and delivery. In this review, innovative designs, as well as interesting antiviral activities of the nanotechnology-inclined biomaterials of Au and Ag, reported in the last 5 years were critically overviewed against several viral diseases affecting man. These include influenza, respiratory syncytial, adenovirus, severe acute respiratory syndromes (SARS), rotavirus, norovirus, measles, chikungunya, HIV, herpes simplex virus, dengue, polio, enterovirus and rift valley fever virus. Notably identified among the nanotechnologically designed promising antiviral agents include
AuNP-M2e peptide vaccine
,
AgNP of cinnamon bark extract
and
AgNP of oseltamivir
for influenza,
PVP coated AgNP
for RSV,
PVP-AgNPs
for SARS-CoV-2,
AuNRs
of a
peptide pregnancy-induce hypertension
and
AuNP nanocarriers
of
antigen
for MERS-CoV and SARS-CoV respectively. Others are
AgNPs of collagen and
Bacillus subtilis
for rotavirus,
AgNPs labelled Ag30-SiO
2
for murine norovirus in water,
AuNPs
of
Allium sativum
and
AgNPs
of
ribavirin
for measles,
AgNPs of
Citrus limetta
and
Andrographis Paniculata
for Chikungunya,
AuNPs
of
efavirenz
and
stavudine
, and
AgNPs-curcumin
for HIV,
NPAuG3-S8
for HSV,
AgNPs of
Moringa oleifera
and
Bruguiera cylindrica
for dengue while
AgNPs
of
polyethyleneimine
and
siRNA
analogues displayed potency against enterovirus. The highlighted candidates are recommended for further translational studies towards antiviral therapeutic designs.